Check-Cap to merge with MBody AI in embodied AI workforce push
EDINBURGH/LONDON - Resolution Therapeutics, a clinical-stage biopharmaceutical company developing regenerative macrophage therapies, announced Wednesday the appointment of Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer. For deeper insights into the biotech sector and to track industry trends, investors can access comprehensive analysis through InvestingPro.
Singah brings over 20 years of corporate and strategic finance experience across UK and US companies. She previously served as CFO at Echopoint Medical and held various finance leadership roles at companies including Amazonia Impact Ventures, Axis Spine Technologies, and GSK. She trained as a Chartered Accountant at EY in Corporate Finance.
Kennedy joins with more than 20 years of business development experience in the pharmaceutical industry. He previously served as Vice President of Business Development at Immunocore plc (NASDAQ:IMCR) and led business development at Achillion Pharmaceuticals before its $930 million acquisition by Alexion Pharmaceuticals (NASDAQ:ALXN). His career also includes positions at Schering-Plough and GSK.
"We are delighted to welcome Lucy and Dan to our leadership team at this exciting time in the Company’s journey, having recently announced the successful dosing of the first patient with RTX001," said Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics, in a press release statement.
The appointments follow Resolution’s recent announcement of dosing the first patient in its Phase I/II EMERALD study of RTX001, an engineered autologous regenerative macrophage therapy designed to treat inflammatory and fibrotic diseases.
The company is focused on developing treatments for conditions including end-stage liver disease, graft-vs-host disease, and lung fibrosis. Resolution Therapeutics is a spinout from the University of Edinburgh and maintains operations in Edinburgh and London. Want to stay ahead in the dynamic biotech sector? InvestingPro offers exclusive analysis and real-time updates on leading pharmaceutical companies and emerging biotechnology firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.